If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Subscribe To Our Newsletter & Stay Updated
